Cargando…

Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase

Lysins (peptidoglycan hydrolases) are promising new protein-based antimicrobial candidates under development to address rising antibiotic resistance encountered among pathogenic bacteria. Exebacase is an antistaphylococcal lysin and the first member of the lysin class to have entered clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vila-Farres, Xavier, Sauve, Karen, Oh, Jun, Swift, Steven, DeJonge, Boudewijn, Ambler, Jane E., Schuch, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580946/ https://www.ncbi.nlm.nih.gov/pubmed/37561151 http://dx.doi.org/10.1128/spectrum.01906-23

Ejemplares similares

The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics
por: Oh, Jun, et al.
Publicado: (2023)

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection
por: Swift, Steven M., et al.
Publicado: (2021)

Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
por: Traczewski, Maria M., et al.
Publicado: (2021)

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
por: Karau, Melissa, et al.
Publicado: (2022)

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing
por: Oh, Jun T., et al.
Publicado: (2021)

711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)
por: Anastasiou, Diane, et al.
Publicado: (2019)

In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires
por: Karau, Melissa J., et al.
Publicado: (2023)

1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus
por: Sauve, Karen, et al.
Publicado: (2017)

712. Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires
por: Karau, Melissa J, et al.
Publicado: (2019)

671. Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Xiong, Yan, et al.
Publicado: (2019)

1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
por: Anastasiou, Diane, et al.
Publicado: (2018)

Intracellular bacteriolysis contributes to pathogenicity of Staphylococcus aureus by exacerbating AIM2-mediated inflammation and necroptosis
por: Feng, Shiyuan, et al.
Publicado: (2022)

Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections
por: Souche, Aubin, et al.
Publicado: (2022)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

1324. Target Attainment of Exebacase, a First-In-Class Antibacterial Lysin, to Determine Optimal Doses for Adult Patients with Staphylococcus aureus (S. aureus) Bloodstream Infections (Bacteremia) Including Endocarditis
por: Ghahramani, Parviz, et al.
Publicado: (2020)

Lipolysis and Bacteriolysis of the Tubercle Bacillus
Publicado: (1918)

Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA and Europe
por: Oh, Jun, et al.
Publicado: (2017)

LB12. Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia
por: Cassino, Cara, et al.
Publicado: (2021)

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance
por: Schuch, Raymond, et al.
Publicado: (2022)

SNAKE VENOM IN RELATION TO HÆMOLYSIS, BACTERIOLYSIS, AND TOXICITY
por: Flexner, Simon, et al.
Publicado: (1902)

Snake Venom in Relation to Hemalysis, Bacteriolysis and Toxicity
Publicado: (1902)

THE RELATION OF BACTERIOLYSIS TO PROTEOLYSIS : STUDIES ON FERMENT ACTION. XVI.
por: Jobling, James W., et al.
Publicado: (1914)

Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia
por: Schuch, Raymond, et al.
Publicado: (2014)

Enhancement of bacteriolysis of Shuffled phage PhiX174 gene E
por: Yu, Shen-ye, et al.
Publicado: (2011)

Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections
por: McCarthy, Matthew W.
Publicado: (2022)

Rapid Screening and Comparison of Chimeric Lysins for Antibacterial Activity against Staphylococcus aureus Strains
por: Park, Jin-Mi, et al.
Publicado: (2023)

Proteomic profiling of lysine acetylation and succinylation in Staphylococcus aureus
por: Xia, Jingyan, et al.
Publicado: (2022)

Lysine Inhibits Hemolytic Activity of Staphylococcus aureus and Its Application in Food Model Contaminated with Staphylococcus aureus
por: Wan, Yangli, et al.
Publicado: (2022)

A switch in surface polymer biogenesis triggers growth-phase-dependent and antibiotic-induced bacteriolysis
por: Flores-Kim, Josué, et al.
Publicado: (2019)

WhyD tailors surface polymers to prevent premature bacteriolysis and direct cell elongation in Streptococcus pneumoniae
por: Flores-Kim, Josué, et al.
Publicado: (2022)

Identification of Lysine Succinylome and Acetylome in the Vancomycin-Intermediate Staphylococcus aureus XN108
por: Tan, Li, et al.
Publicado: (2022)

Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection
por: Ferry, Tristan, et al.
Publicado: (2021)

Expression and lytic efficacy assessment of the Staphylococcus aureus phage SA4 lysin gene
por: Mishra, Anil Kumar, et al.
Publicado: (2013)

Characterization of a New Staphylococcus aureus Kayvirus Harboring a Lysin Active against Biofilms
por: Melo, Luís D. R., et al.
Publicado: (2018)

Guanylate-binding proteins promote AIM2 inflammasome activation during Francisella novicida infection by inducing cytosolic bacteriolysis and DNA release
por: Meunier, Etienne, et al.
Publicado: (2015)

Complete Genome Sequence of Staphylococcus aureus Phage GRCS
por: Swift, Steven M., et al.
Publicado: (2014)

Malonyl-proteome profiles of Staphylococcus aureus reveal lysine malonylation modification in enzymes involved in energy metabolism
por: Shi, Yanan, et al.
Publicado: (2021)

In-situ and Real-Time Monitoring of the Interaction Between Lysins and Staphylococcus aureus Biofilm by Surface Plasmon Resonance
por: Hong, Wei, et al.
Publicado: (2021)

LB3. Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared with Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study
por: Cassino, Cara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gkatf66sv19knaflqmoaqb7n76